Thus, the findings of the study have identified a new genetic mutation causing neuronal hyperexcitation, leading to migraine headaches. This also explains why migraines tend to be hereditary and run in families.
Scope of Study
The study has identified a possible therapeutic target namely the K2P2.1 protein
which can be inhibited by drugs, which in turn would reduce neuronal excitation and prevent migraines. In fact a patent has been filed in this regard.
Migraine is a severe form of a headache associated with other symptoms such as nausea
, increased sensitivity to light and sound and tingling in the arms and legs. The headache
can last for hours to days and at times the pain can be severe and disabling and keep people away from work.
Migraine is treated by drugs that can either relieve an acute attack or if recurrent attacks occur preventive medications can help from reoccurring. However, available treatments do not offer relief in nearly half the cases, prompting the need to look for better and more effective treatments.
Future Research Opportunities from Current Study
The finding of a new mechanism of genetic mutation where two proteins are produced instead of the usual one protein may open up research opportunities for determining the mechanism of causation of other genetic diseases as well and ways to diagnose them.
In conclusion, the findings of the study have not only paved the way for developing better migraine drugs but also outlining a new mechanism of causation of genetic diseases in general which can be used for further research into genetic diseases and their diagnosis. Reference :
- Migraine-Associated TRESK Mutations Increase Neuronal Excitability through Alternative Translation Initiation and Inhibition of TREK - (https://doi.org/10.1016/j.neuron.2018.11.039)